Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
-
br Implementation of sacubitril valsartan into clinical prac
2023-10-27
Implementation of sacubitril/valsartan into clinical practice Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial; NYHA functional class II–IV, reduced left ventricular ejectio
-
In addition a substantial knowledge has been gained about th
2023-10-27
In addition, a substantial knowledge has been gained about the main properties of AT1R, such as ligand preference, signaling, regulation, and trafficking. However, it is less known how AT1R and other plasma membrane receptors affect each other’s function, and how these crosstalk mechanisms can be ut
-
A phase I trial has recently evaluated enzalutamide an
2023-10-27
A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with
-
The G R mutation is
2023-10-27
The G1202R mutation is located at the solvent front of the ALK kinase domain adjacent to the inhibitor's binding pocket. Although barely reported in the setting of crizotinib resistance, it has emerged as the most refractory mutation to both the first- and second-generation ALK inhibitors. The large
-
br Regulation of AHR Activity AHR activity is
2023-10-27
Regulation of AHR Activity AHR activity is regulated in various ways. First, AHR protein levels are controlled via ubiquitin-mediated proteosomal degradation: Ligand binding induces AHR ubiquitination and subsequent degradation by the proteasome [5]. AIP, a component of the AHR chaperone complex,
-
According to average serum fat content
2023-10-27
According to average serum fat content of 6.9 g/L (Phillips et al., 1989) and serum dioxin level from individuals exposed to dioxins as the result of accidents in Seveso (Needham et al., 1997), Taiwan (Guo et al., 2004) and Vietnam (The Tai et al., 2011) the median serum concentration of TCDD would
-
br Adenosine and tumor microenvironment In the majority
2023-10-27
Adenosine and tumor microenvironment In the majority of carcinogenic processes a proinflammatory state is generated [36], [37]. In addition, a tumor hypoxic environment is generally due to inadequate perfusion of oxygen to the tumor [38]. Immunomodulators are molecules that regulate the immune r
-
In the olfactory bulb expression was
2023-10-27
In the olfactory bulb, expression was especially prominent in the mitral cell layer from embryonic stages to adult tissues (Figs. 1D–G). By E14–E16, Ack1 signal was remarkably intense in the proliferative ventricular zone (Fig. 1D). From E18 to adult, expression was also observed in glomerular and g
-
The following are the supplementary data related to this art
2023-10-27
The following are the supplementary data related to this article. Funding Work in Dr. Rosell's laboratory is partially supported by a grant from La Caixa Foundation, and an Instituto de Salud Carlos III grant (RESPONSE, PIE16/00011). Work in Dr. Cao's laboratory is partially supported by the Maj
-
Further analysis sought to understand the
2023-10-27
Further analysis sought to understand the mechanism associated with the autotaxin-mediated increase of miR-489-3p in circulation. Based upon sequence complementarity, DIANA TarBase predicted miR-489-3p targets MAPK2K1, or MEK1, an oncogene widely dysregulated in cancer (Fig. 4A). To test this relati
-
(R)-PFI 2 hydrochloride br Dual role of autophagy in human d
2023-10-27
Dual role of autophagy in human diseases Emerging evidence suggests that autophagy serves as a double-edged sword in several human diseases, such as CNS diseases (Rubinsztein et al., 2015), arteriosclerosis (Schrijvers et al., 2011) and cancer (Ozpolat and Benbrook, 2015). Likewise, currently the
-
The known crystal structures of class
2023-10-27
The known crystal structures of class C GPCR VFTs do not include attached TM domains, therefore current conformational data may not accurately reflect the dynamics of extracellular domains in full-length receptors. Nevertheless, compelling mechanisms of signal transduction can still be postulated. S
-
Weak and transient interactions of HMGB
2023-10-26
Weak and transient interactions of HMGB proteins in such hit-and-run mechanisms are understandable given that “fluorescence loss in photobleaching” (FLIP) experiments employing GFP-labeled HMGBs have shown that in living cells they are the most mobile of all nuclear proteins [144]. The entire pool o
-
uk5099 It was reported that oral administration
2023-10-26
It was reported that oral administration of CSZ to C57BL/6J mice significantly improved spatial learning and memory, and prevented Aβ-induced immunoresponse in Aβ25-35-injected mice. However, post-treatment with CSZ after Aβ25-35 administration, when Aβ was already accumulated, did not prevent Aβ-in
-
Some of the mechanisms that involve LOX as a potential
2023-10-26
Some of the mechanisms that involve 12-LOX as a potential pathogenic enzyme are illustrated in Fig. 2. Direct β cell effects associated with the stimulation of 12-LOX activity include the activation of second messengers c-Jun N-terminal kinase and p38 MAPK, both of which show increased phosphorylati
13434 records 175/896 page Previous Next First page 上5页 171172173174175 下5页 Last page